BEIJING, April 10 (Reuters): The China National Biotec Group Company (CNBG) has obtained regulatory approval to move a third COVID-19 vaccine candidate into the human testing stage in China, CNBG said on Saturday.
The subsidiary of state-owned China National Pharmaceutical Group (Sinopharm) said that manufacturing the candidate, which is based on protein cultivated in factories, does not require facilities with high biosafety levels.
